Trials / Unknown
UnknownNCT01449604
Stereotactic Radiation in Vestibular Schwannoma
Randomized Comparison of Steretotactic Radiosurgery and Hypofractionated Steretotactic Radiotherapy in the Treatment of Vestibular Schwannoma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Ramathibodi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether stereotactic radiosurgery (SRS)and stereotactic radiotherapy (SRT)are effective in the treatment of vestibular schwannoma (VS).
Detailed description
Vestibular schwannomas (VSs) are slow-growing tumors of the myelin-forming cells that cover cranial nerve VIII.The treatment options for patients with VSs include active observation, surgical management, and radiotherapy. However, the optimal treatment choice remain controversial. Over the past 10 years, there has been rapid progress in the application of stereotactic radiotherapy to the treatment of VSs. The stereotactic radiotherapy program includes single fraction radiosurgery (SRS) and hypofraction stereotactic radiotherapy (HSRT) are commonly used for VSs treatment. Since SRS and SRT techniques differ significantly enough to raise questions of therapeutic advantage and until now, there is no prospective, randomized study comparing the outcomes for patients treated using both radiotherapy techniques. We designed the first prospective randomized protocol to compare SRS and SRT for answer this question.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | stereotactic radiotherapy | Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions |
| RADIATION | stereotactic radiosurgery | Radio surgery 12 Gy |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2011-10-10
- Last updated
- 2011-10-10
Source: ClinicalTrials.gov record NCT01449604. Inclusion in this directory is not an endorsement.